CSE: RVV, OTC: RVVTF
Revenue (ttm)
Gross Profit (ttm)
Diluted EPS (ttm)
Mr. Michael Frank
Chairman & CEO
Mr. Carmelo Marrelli ACIS, B.Comm., CA, CGA, CPA
Chief Financial Officer
Dr. Kelly T. McKee Jr., M.D., M.P.H.
Chief Scientific Officer Consultant
Dr. Onesmo Mpanju Ph.D.
Chief Regulatory Affairs Consultant
Mr. Derrick Alexander Welsh
COO of Psilocin Pharma
Market Capitalization
$27,421,880
Shares Outstanding
163,946,282
Shares Short (% of Float)
()
Insider Ownership
2%